{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:36:35Z","timestamp":1794566195583,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      This real-world study assessed the epidemiology and clinical complications of\n                      <jats:italic>Clostridioides difficile<\/jats:italic>\n                      infections (CDIs) and recurrences (rCDIs) in hospital and community settings in Germany from 2015\u2009\u2212\u20092019.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An observational retrospective cohort study was conducted among adult patients diagnosed with CDI in hospital and community settings using statutory health insurance claims data from the BKK database. A cross-sectional approach was used to estimate the annual incidence rate of CDI and rCDI episodes per 100,000 insurants. Patients\u2019 demographic and clinical characteristics were described at the time of first CDI episode. Kaplan-Meier method was used to estimate the time to rCDIs and time to complications (colonic perforation, colectomy, loop ileostomy, toxic megacolon, ulcerative colitis, peritonitis, and sepsis). A Cox model was used to assess the risk of developing complications, with the number of rCDIs as a time-dependent covariate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 15,402 CDI episodes were recorded among 11,884 patients. The overall incidence of CDI episodes declined by 38% from 2015 to 2019. Most patients (77%) were aged\u2009\u2265\u200965 years. Around 19% of CDI patients experienced at least one rCDI. The median time between index CDI episode to a rCDI was 20 days. The most frequent complication within 12-months of follow-up after the index CDI episode was sepsis (7.57%), followed by colectomy (3.20%). The rate of complications increased with the number of rCDIs. The risk of any complication increased by 31% with each subsequent rCDI (adjusted hazard ratio [HR]: 1.31, 95% confidence interval: 1.17;1.46).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CDI remains a public health concern in Germany despite a decline in the incidence over recent years. A substantial proportion of CDI patients experience rCDIs, which increase the risk of severe clinical complications. The results highlight an increasing need of improved therapeutic management of CDI, particularly efforts to prevent rCDI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-024-09218-y","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T09:02:52Z","timestamp":1711530172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Epidemiological and clinical burden of Clostridioides difficile infections and recurrences between 2015\u2009\u2212\u20092019: the RECUR Germany study"],"prefix":"10.1186","volume":"24","author":[{"given":"Aurore","family":"Tricotel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Wilk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Dombrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Rinta-Kokko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik L.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrata","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"issue":"13","key":"9218_CR1","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","volume":"370","author":"SS Magill","year":"2014","unstructured":"Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198\u2013208.","journal-title":"N Engl J Med"},{"issue":"7","key":"9218_CR2","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s10096-019-03539-6","volume":"38","author":"J Czepiel","year":"2019","unstructured":"Czepiel J, Drozdz M, Pituch H, Kuijper EJ, Perucki W, Mielimonka A, et al. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis. 2019;38(7):1211\u201321.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"9218_CR3","doi-asserted-by":"publisher","first-page":"010417","DOI":"10.7189\/jogh.07.010417","volume":"7","author":"P Eze","year":"2017","unstructured":"Eze P, Balsells E, Kyaw MH, Nair H. Risk factors for Clostridium difficile infections - an overview of the evidence base and challenges in data synthesis. J Glob Health. 2017;7(1):010417.","journal-title":"J Glob Health"},{"key":"9218_CR4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3389\/fmicb.2018.00646","volume":"9","author":"H Schaffler","year":"2018","unstructured":"Schaffler H, Breitruck A. Clostridium difficile - from colonization to infection. Front Microbiol. 2018;9:646.","journal-title":"Front Microbiol"},{"issue":"3","key":"9218_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3390\/antibiotics10030299","volume":"10","author":"J Czepiel","year":"2021","unstructured":"Czepiel J, Krutova M, Mizrahi A, Khanafer N, Enoch DA, Patyi M, et al. Mortality following Clostridioides difficile infection in Europe: a retrospective Multicenter Case-Control Study. Antibiot (Basel). 2021;10(3):299.","journal-title":"Antibiot (Basel)"},{"key":"9218_CR6","doi-asserted-by":"publisher","first-page":"16020","DOI":"10.1038\/nrdp.2016.20","volume":"2","author":"WK Smits","year":"2016","unstructured":"Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nat Rev Dis Primers. 2016;2:16020.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"9218_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s41687-020-0179-1","volume":"4","author":"L Lurienne","year":"2020","unstructured":"Lurienne L, Bandinelli PA, Galvain T, Coursel CA, Oneto C, Feuerstadt P. Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey. J Patient Rep Outcomes. 2020;4(1):14.","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"9218_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12955-019-1081-5","volume":"17","author":"F Barbut","year":"2019","unstructured":"Barbut F, Galperine T, Vanhems P, Le Monnier A, Durand-Gasselin B, Canis F, et al. Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting. Health Qual Life Outcomes. 2019;17(1):6.","journal-title":"Health Qual Life Outcomes"},{"issue":"11","key":"9218_CR9","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1007\/s10620-018-5222-1","volume":"63","author":"K Heinrich","year":"2018","unstructured":"Heinrich K, Harnett J, Vietri J, Chambers R, Yu H, Zilberberg M. Impaired quality of Life, Work, and activities among adults with Clostridium difficile infection: a multinational survey. Dig Dis Sci. 2018;63(11):2864\u201373.","journal-title":"Dig Dis Sci"},{"issue":"2","key":"9218_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.cmi.2014.08.017","volume":"21","author":"MA Olsen","year":"2015","unstructured":"Olsen MA, Yan Y, Reske KA, Zilberberg MD, Dubberke ER. Recurrent Clostridium difficile infection is associated with increased mortality. Clin Microbiol Infect. 2015;21(2):164\u201370.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"9218_CR11","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1186\/s12879-021-06147-y","volume":"21","author":"E Finn","year":"2021","unstructured":"Finn E, Andersson FL, Madin-Warburton M. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI. BMC Infect Dis. 2021;21(1):456.","journal-title":"BMC Infect Dis"},{"key":"9218_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-3-319-72799-8_8","volume":"1050","author":"F Fitzpatrick","year":"2018","unstructured":"Fitzpatrick F, Skally M, Brady M, Burns K, Rooney C, Wilcox MH. European practice for CDI Treatment. Adv Exp Med Biol. 2018;1050:117\u201335.","journal-title":"Adv Exp Med Biol"},{"issue":"Suppl 2","key":"9218_CR13","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","volume":"27","author":"J van Prehn","year":"2021","unstructured":"van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, et al. European Society of Clinical Microbiology and Infectious diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect. 2021;27(Suppl 2):S1\u201321.","journal-title":"Clin Microbiol Infect"},{"key":"9218_CR14","unstructured":"European Centre for Disease Prevention and Control. Clostridioides (Clostridium) difficile infections Annual Epidemiological Report for 2016\u20132017. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/clostridium-difficile-infections-annual-epidemiological-report-2016-2017. Accessed 1 Dec 2022."},{"issue":"1","key":"9218_CR15","doi-asserted-by":"publisher","first-page":"010407","DOI":"10.7189\/jogh.09.010407","volume":"9","author":"E Balsells","year":"2019","unstructured":"Balsells E, Shi T, Leese C, Lyell I, Burrows J, Wiuff C, Campbell H, Kyaw MH, Nair H. Global burden of Clostridium difficile infections: a systematic review and meta-analysis. J Glob Health. 2019;9(1):010407.","journal-title":"J Glob Health"},{"key":"9218_CR16","doi-asserted-by":"crossref","unstructured":"Vehreschild M, Schreiber S, von Muller L, Epple HJ, Weinke T, Manthey C, Oh J, Wahler S, Stallmach A. Trends in the epidemiology of Clostridioides difficile infection in Germany. Infection. 2023:1\u20138.","DOI":"10.1007\/s15010-023-02044-5"},{"issue":"4","key":"9218_CR17","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40121-023-00785-2","volume":"12","author":"G Brestrich","year":"2023","unstructured":"Brestrich G, Angulo FJ, Berger FK, Brosamle C, Hagel S, Leischker A, et al. Epidemiology of Clostridioides difficile infections in Germany, 2010\u20132019: a review from four public databases. Infect Dis Ther. 2023;12(4):1057\u201372.","journal-title":"Infect Dis Ther"},{"issue":"11","key":"9218_CR18","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139.","journal-title":"Med Care"},{"key":"9218_CR19","unstructured":"Centers for Disease Control and Prevention. 2014 Annual Report for the Emerging Infections Program for Clostridium difficile Infection. https:\/\/www.cdc.gov\/hai\/eip\/pdf\/cdiff\/2014-Annual-CDI-Report.pdf. Accessed 1 Dec 2022."},{"key":"9218_CR20","unstructured":"Centers for Disease Control and Prevention. 2015 Annual Report for the Emerging Infections Program for Clostridium difficile Infection. https:\/\/www.cdc.gov\/hai\/eip\/pdf\/cdiff\/2015-CDI-Report.pdf. Accessed 1 Dec 2022."},{"key":"9218_CR21","unstructured":"Centers for Disease Control and Prevention. 2016 Annual Report for the Emerging Infections Program for Clostridium difficile Infection. https:\/\/www.cdc.gov\/hai\/eip\/pdf\/cdiff\/2016-CDI-Report-H.pdf. Accessed 1 Dec 2022."},{"key":"9218_CR22","unstructured":"Centers for Disease Control and Prevention. 2017 Annual Report for the Emerging Infections Program for Clostridioides difficile Infection. https:\/\/www.cdc.gov\/hai\/eip\/pdf\/cdiff\/2017-CDI-Report-H.pdf. Accessed 1 Dec 2022."},{"key":"9218_CR23","unstructured":"Centers for Disease Control and Prevention. Emerging Infections Program Healthcare-Associated Infections\u2013Community Interface Report Clostridioides difficile infection. 2018. https:\/\/www.cdc.gov\/hai\/eip\/pdf\/cdiff\/2018-CDI-Report-H.pdf. Accessed 1 Dec 2022."},{"key":"9218_CR24","unstructured":"Centers for Disease Control and Prevention. Emerging Infections Program Healthcare-Associated Infections\u2013Community Interface Report Clostridioides difficile infection, 2019 https:\/\/www.cdc.gov\/hai\/eip\/Annual-CDI-Report-2019.html. Accessed 1 Dec 2022."},{"issue":"14","key":"9218_CR25","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","volume":"382","author":"AY Guh","year":"2020","unstructured":"Guh AY, Mu Y, Winston LG, Johnston H, Olson D, Farley MM, et al. Trends in U.S. Burden of Clostridioides difficile infection and outcomes. N Engl J Med. 2020;382(14):1320\u201330.","journal-title":"N Engl J Med"},{"issue":"7\u20138","key":"9218_CR26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.14745\/ccdr.v45i78a04","volume":"45","author":"Y Xia","year":"2019","unstructured":"Xia Y, Tunis MC, Frenette C, Katz K, Amaratunga K, Rose SR, House A, Quach C. Epidemiology of Clostridioides difficile infection in Canada: a six-year review to support vaccine decision-making. Can Commun Dis Rep. 2019;45(7\u20138):191\u2013211.","journal-title":"Can Commun Dis Rep"},{"issue":"35","key":"9218_CR27","doi-asserted-by":"publisher","first-page":"1800638","DOI":"10.2807\/1560-7917.ES.2019.24.35.1800638","volume":"24","author":"M Colomb-Cotinat","year":"2019","unstructured":"Colomb-Cotinat M, Assouvie L, Durand J, Daniau C, Leon L, Maugat S, et al. Epidemiology of Clostridioides difficile infections, France, 2010 to 2017. Euro Surveill. 2019;24(35):1800638.","journal-title":"Euro Surveill"},{"key":"9218_CR28","unstructured":"European Centre for Disease Prevention and Control. European Surveillance of Clostridioides (Clostridium) difficile infections Surveillance protocol version 2.4 https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/clostridium-difficile-infections-EU-surveillance-protocol-vers2.4.pdf. Accessed 1 Dec 2022."},{"issue":"4","key":"9218_CR29","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3201\/eid1404.071023","volume":"14","author":"F Burckhardt","year":"2008","unstructured":"Burckhardt F, Friedrich A, Beier D, Eckmanns T. Clostridium difficile surveillance trends, Saxony, Germany. Emerg Infect Dis. 2008;14(4):691\u20132.","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"9218_CR30","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40121-016-0135-9","volume":"5","author":"C Lubbert","year":"2016","unstructured":"Lubbert C, Zimmermann L, Borchert J, Horner B, Mutters R, Rodloff AC. Epidemiology and recurrence rates of Clostridium difficile infections in Germany: a Secondary Data Analysis. Infect Dis Ther. 2016;5(4):545\u201354.","journal-title":"Infect Dis Ther"},{"issue":"9759","key":"9218_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0140-6736(10)61266-4","volume":"377","author":"MP Bauer","year":"2011","unstructured":"Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011;377(9759):63\u201373.","journal-title":"Lancet"},{"issue":"2","key":"9218_CR32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1017\/ice.2014.39","volume":"36","author":"L Furuya-Kanamori","year":"2015","unstructured":"Furuya-Kanamori L, Stone JC, Clark J, McKenzie SJ, Yakob L, Paterson DL, Riley TV, Doi SA, Clements AC, Comorbidities. Exposure to medications, and the risk of Community-Acquired Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015;36(2):132\u201341.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"9218_CR33","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1186\/s12879-016-2027-8","volume":"16","author":"A Pechal","year":"2016","unstructured":"Pechal A, Lin K, Allen S, Reveles K. National age group trends in Clostridium difficile infection incidence and health outcomes in United States Community hospitals. BMC Infect Dis. 2016;16(1):682.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"9218_CR34","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jac\/dkr508","volume":"67","author":"MP Hensgens","year":"2012","unstructured":"Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012;67(3):742\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"9218_CR35","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/ajg.2012.179","volume":"107","author":"S Janarthanan","year":"2012","unstructured":"Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001\u201310.","journal-title":"Am J Gastroenterol"},{"key":"9218_CR36","doi-asserted-by":"publisher","first-page":"205031212098673","DOI":"10.1177\/2050312120986733","volume":"9","author":"P Feuerstadt","year":"2021","unstructured":"Feuerstadt P, Boules M, Stong L, Dahdal DN, Sacks NC, Lang K, Nelson WW. Clinical complications in patients with primary and recurrent Clostridioides difficile infection: a real-world data analysis. SAGE Open Med. 2021;9:2050312120986733.","journal-title":"SAGE Open Med"},{"issue":"5","key":"9218_CR37","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1093\/cid\/civ958","volume":"62","author":"C Sheitoyan-Pesant","year":"2016","unstructured":"Sheitoyan-Pesant C, Abou Chakra CN, Pepin J, Marcil-Heguy A, Nault V, Valiquette L. Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile infection. Clin Infect Dis. 2016;62(5):574\u201380.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"9218_CR38","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s40121-023-00800-6","volume":"12","author":"T Weinke","year":"2023","unstructured":"Weinke T, Beier D, Brestrich G, von Eiff C, Hackl D, Heinrich K, Moisi J, Schley K. Epidemiology and risk factors of Clostridioides difficile infections in Germany: A Health Claims Data Analysis. Infect Dis Ther. 2023;12(5):1299\u2013317.","journal-title":"Infect Dis Ther"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09218-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09218-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09218-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T09:03:12Z","timestamp":1711530192000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09218-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9218"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09218-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,27]]},"assertion":[{"value":"14 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used administrative claims data that fulfils all necessary requirements of data protection in Germany. Consent to participate is not applicable. According to the Good Practice in Secondary Data Analysis, published by the Working Group for the Survey and Utilization of Secondary Data (AGENS) with representatives from the German Society for Social Medicine and Prevention (DGSMP) and the German Society for Epidemiology (DGEpi), no clearance by ethics committee is necessary for studies using anonymized secondary data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FLA was at the time of the study employed by Ferring Pharmaceuticals A\/S. AT, AA, SD, and HRK are employed by IQVIA. AW is employed by Team Gesundheit. SG is a member of steering committees for Janssen, Bristol Myers Squibb and Abbvie, participates in drug monitoring committees for Janssen, has speaker commitments for Abbvie, Takeda, Janssen, Pfizer, Gilead, Galapagos, Ferring Pharmaceuticals A\/S, Eli-Lilly, Celltrion, and is a member of advisory committees for Janssen, Abbvie, Takeda, Gilead, Galapagos, Eli-Lilly, Pfizer, Celltrion, and Ferring Pharmaceuticals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"357"}}